Vigabatrin, a GABA aminotransferase (GABA-AT) inactivator, is used to treat infantile spasms and refractory complex partial seizures and is in clinical trials to treat addiction. We evaluated a novel GABA-AT inactivator (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115, compound 1) and observed that it does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. By use of in vivo microdialysis techniques in freely moving rats and microPET imaging techniques, 1 produced similar inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens at (1)/(300) to (1)/(600) the dose of vigabatrin. It also blocks expression of cocaine-induced conditioned place preference at a dose (1)/(300) that of vigabatrin. Electroretinographic (ERG) responses in rats treated with 1, at doses 20-40 times higher than those needed to treat addiction in rats, exhibited reductions in ERG responses, which were less than the reductions observed in rats treated with vigabatrin at the same dose needed to treat addiction in rats. In conclusion, 1 can be administered at significantly lower doses than vigabatrin, which suggests a potential new treatment for addiction with a significantly reduced risk of visual field defects.
Vigabatrin, a n class="Gene">GABA aminotransferase (GABA-AT) inactivator, is used to treat infantile spasms and refractory complex partial seizures and is in clinical trials to treat addiction. We evaluated a novel GABA-AT inactivator (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115, compound 1) and observed that it does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. By use of in vivo microdialysis techniques in freely moving rats and microPET imaging techniques, 1 produced similar inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens at (1)/(300) to (1)/(600) the dose of vigabatrin. It also blocks expression of cocaine-induced conditioned place preference at a dose (1)/(300) that of vigabatrin. Electroretinographic (ERG) responses in rats treated with 1, at doses 20-40 times higher than those needed to treat addiction in rats, exhibited reductions in ERG responses, which were less than the reductions observed in rats treated with vigabatrin at the same dose needed to treat addiction in rats. In conclusion, 1 can be administered at significantly lower doses than vigabatrin, which suggests a potential new treatment for addiction with a significantly reduced risk of visual field defects.
Authors: John M Pellock; Edward Faught; Robert C Sergott; W Donald Shields; Gregory A Burkhart; Gregory L Krauss; Rod Foroozan; David L Wesche; Mark A Weinberg Journal: Epilepsy Behav Date: 2011-10-05 Impact factor: 2.937
Authors: S L Dewey; A E Morgan; C R Ashby; B Horan; S A Kushner; J Logan; N D Volkow; J S Fowler; E L Gardner; J D Brodie Journal: Synapse Date: 1998-10 Impact factor: 2.562
Authors: Hoang V Le; Dustin D Hawker; Rui Wu; Emma Doud; Julia Widom; Ruslan Sanishvili; Dali Liu; Neil L Kelleher; Richard B Silverman Journal: J Am Chem Soc Date: 2015-03-30 Impact factor: 15.419
Authors: Hyunbeom Lee; Hoang V Le; Rui Wu; Emma Doud; Ruslan Sanishvili; John F Kellie; Phillip D Compton; Boobalan Pachaiyappan; Dali Liu; Neil L Kelleher; Richard B Silverman Journal: ACS Chem Biol Date: 2015-07-06 Impact factor: 5.100
Authors: Christopher D McCune; Matthew L Beio; Jill M Sturdivant; Roberto de la Salud-Bea; Brendan M Darnell; David B Berkowitz Journal: J Am Chem Soc Date: 2017-09-28 Impact factor: 15.419
Authors: Jose I Juncosa; Kenji Takaya; Hoang V Le; Matthew J Moschitto; Pathum M Weerawarna; Romila Mascarenhas; Dali Liu; Stephen L Dewey; Richard B Silverman Journal: J Am Chem Soc Date: 2018-01-30 Impact factor: 15.419